Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 5,400 Shares

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Novavax Price Performance

NVAX stock traded up $0.53 during mid-day trading on Thursday, reaching $8.57. 3,813,721 shares of the company’s stock were exchanged, compared to its average volume of 9,060,255. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The stock’s 50 day moving average is $8.74 and its 200 day moving average is $11.40. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -3.79 and a beta of 2.02.

Novavax (NASDAQ:NVAX) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to analysts’ expectations of $65.80 million. The company’s quarterly revenue was down 54.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.26) EPS. On average, research analysts forecast that Novavax, Inc. will post -1.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. B. Riley reaffirmed a “buy” rating and set a $26.00 target price (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, Jefferies Financial Group decreased their price target on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $17.83.

Institutional Trading of Novavax

Institutional investors and hedge funds have recently modified their holdings of the stock. Banque Cantonale Vaudoise raised its stake in Novavax by 500.0% in the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,500 shares during the last quarter. Amalgamated Bank raised its position in shares of Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares during the last quarter. Signaturefd LLC lifted its stake in shares of Novavax by 214.5% in the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 3,874 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 1,598 shares during the last quarter. Finally, Midland Wealth Advisors LLC purchased a new stake in Novavax during the 2nd quarter valued at about $152,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.